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TGF-b–activating sequence mimicked most effects of the typeThrombospondin peptides are potent inhibitors of mesangial
I peptide. The mechanism of action of these peptides mayand glomerular endothelial cell proliferation in vitro and in vivo.
include antagonism of fibroblast growth factor-2 and alterationBackground. Thrombospondin 1 (TSP1), a multifunctional,
of MC adhesion. The TGF-b–activating sequence alone did notmatricellular glycoprotein, is expressed de novo in many in-
have significant effects on mesangial or glomerular endothelialflammatory disease processes, including glomerular disease.
cells in vitro or in experimental kidney disease in vivo.Short peptide fragments derived from the type I properdin
Conclusion. Peptides from TSP1 may be promising therapeu-repeats of the TSP1 molecule mimic anti-angiogenic and/or
tics in treating glomerular disease with mesangial and endothe-transforming growth factor-b (TGF-b)–activating properties
lial cell injury.of the whole TSP1 glycoprotein. We investigated the effects
of d-reverse peptides derived from the type I domain of TSP1
in experimental mesangial proliferative glomerulonephritis in
the rat (anti-Thy1 model), as well as their effects on cultured
Glomerular disease is a major cause of end-stage renalmesangial and glomerular endothelial cells.
disease in humans. Mesangial proliferative glomerulone-Methods. Effects of TSP peptides on proliferation of mesan-
gial or glomerular endothelial cells in culture after growth phritis, the most common type of glomerulonephritis in
arrest or growth factor stimulation (fibroblast growth factor-2, the Western world [1], is characterized by mesangial cell
platelet-derived growth factor-BB, 10% fetal calf serum) were (MC) proliferation, activation, and matrix expansion,measured by [3H]thymidine incorporation assay. Adhesion of
and it occasionally progresses to end-stage renal failurerat mesangial cells (MCs) to a TSP-peptide matrix was assayed
[2]. Recently, our group has studied the anti-Thy1 modelusing an attachment-hexosaminidase assay. TSP peptides were
intraperitoneally injected daily in rats that had received an of mesangial proliferative glomerulonephritis in the rat
intravenous injection of polyclonal anti-Thy1 antibody to in- [2, 3]. In this model, a single injection of antithymocyte
duce mesangial proliferative glomerulonephritis. On biopsies
antibody results in an acute, complement-dependent MCfrom days 2, 5, and 8 of anti-Thy1 disease, mesangial and
injury (days 0 to 2) with proteinuria, followed by a fibro-glomerular endothelial proliferation, matrix expansion, mesan-
gial activation, and microaneurysm formation were assessed. blast growth factor-2 (FGF-2)– and platelet-derived growth
Functional parameters such as blood pressure and proteinuria factor (PDGF)–dependent MC proliferative response
were also measured. that is accompanied by overproduction of extracellular
Results. An 18-amino acid peptide (type I peptide) with anti-
matrix proteins (days 3 to 10) [2]. In addition, dissolutionangiogenic and TGF-b–activating sequences decreased mesan-
of the mesangium adversely affects the glomerular capil-gial and glomerular endothelial cell proliferation in vitro and
in vivo and reduced microaneurysm formation and proteinuria lary wall architecture, resulting in glomerular endothelial
in experimental glomerulonephritis. Analogues lacking the cell (GEN) injury and proliferation, as well as capillary
ballooning with stretching of the endothelium and occa-
sional GEN rupture leading to the formation of micro-Key words: thrombospondin, inflammation, mesangial cells, glomeru-
lar endothelial cells, cell proliferation, proteinuria, microaneurysm. aneurysms [3].
Recently, our group has demonstrated the involve-Received for publication October 19, 1998
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cell types. TSP1 expression is also regulated by various
cytokines such as PDGF, FGF-2, or transforming growth
factor-b (TGF-b) and is frequently expressed at sites of
inflammation and wound healing [5]. The loss of TSP1
expression in TSP1-null mice produces inflammatory
lung disease [6]. In vitro studies in various cell types have
demonstrated multiple functions of TSP1 in modulating
platelet aggregation, angiogenesis, cell proliferation, cell
adhesion and migration, and TGF-b activity [5]. In the
anti-Thy1 model of mesangial proliferative glomerulone-
Fig. 1. Schematic outline of the experimental design (also describedphritis, a marked de novo expression of TSP1 by MCs
in the Methods section).(peak on day 5) was restricted to the MC proliferative
phase of the disease, and TSP1 expression was regulated
by FGF-2 and PDGF [4]. The expression of TSP1 by
MCs [4] also coincided with the suppression of GEN to all d-reverse peptides was also investigated. Experi-
proliferation on day 3 and 5 in this model [3, 4]. mental mesangial proliferative glomerulonephritis was
The function of TSP1 in vivo may include both antipro-
induced using a polyclonal anti-Thy1 antibody. After a
liferative and anti-inflammatory activities [6], and dis-
series of pilot studies with different concentrations and
tinct fragments of the TSP1 molecule have been identi-
ways of application of the TSP peptides, the type I pep-
fied with specific in vitro effects. Recent work by Roberts,
tide and the control peptide, as well as specific peptidesMurphy-Ullrich, and others [7–13] has identified several
with either the anti-angiogenic or TGF-b–activating se-peptide sequences within the properdin-like type I do-
quence were given intravenously daily to diseased ani-main of the TSP1 molecule that inhibit aortic endothelial
mals that were injected with anti-Thy1 antibody to inves-cell proliferation and angiogenesis (SHWSPWSS) [7],
tigate the influence of these peptides on the MC and/oractivate latent TGF-b (KRFK) [8–10], bind to heparin
GEN response to injury in vivo (Fig. 1). Tissues from[11] and to the gelatin-binding domain of fibronectin
different time points of this experiment were analyzed(GGWSHW) [12]. Retro-inverso analogues of these
in regard to mesangiolysis, proliferation of MCs andTSP1 peptides retain their specific properties but have
GEN, matrix formation, and microaneurysm formation.increased circulatory half-life because of resistance to
proteolytic degradation in vivo [13]. Thrombospondin peptides
Therefore, we investigated the effects of TSP1 pep-
The peptides used in this study (Table 1) were synthe-tides in experimental mesangial proliferative nephritis
sized, purified, and analyzed as described elsewherein the rat. TSP homologue peptides from the type I
[11–13]. Peptides were prepared as stable retro-inversodomain effectively inhibit MCs and GEN proliferation
analogues to prevent them from rapid digestion by ubiq-in vitro and in vivo and reduce microaneurysm formation
uitous peptidases. The control peptide 513 is inactive inand proteinuria by improved renal function in this model,
all in vitro assays in regard to cell adhesion, proliferation,suggesting a potential role for TSP peptides in the treat-
and TGF-b activation, as well as in in vivo experimentsment of kidney disease.
[12–14].
METHODS Mesangial and glomerular endothelial cell
culture experimentsExperimental design
All cell culture experiments were done in triplicate.The effects of a D-reverse 18-amino acid peptide de-
To determine if TSP peptides affect MC or GEN prolif-rived from the type I domain (peptide 416) of the TSP1
eration in vitro, rat MCs (passage 18 to 25) and rat GENmolecule were compared with a control peptide (peptide
(passage 30 to 38) were prepared, characterized, and513) in both in vitro and in vivo studies [13]. To investigate
maintained as described previously [15, 16]. MCs orthe role of the known anti-angiogenic and TGF-b–
GEN were plated in 10% FCS, were allowed to attachactivating properties in the action of this type I peptide,
overnight, and were growth arrested in 0.5% FCS forhomologous peptides with the anti-angiogenic or TGF-b–
three days. Cultured cells were then washed three timesactivating sequences were also tested. In in vitro experi-
with Hank’s balanced salt solution (HBSS) and eitherments, the effect of the peptides on unstimulated, FGF-2–,
further grown in 0.5% FCS (serum-starved group) orPDGF-BBB, or 10% fetal calf serum (FCS)–stimulated
stimulated for 24 or 40 hours with 10% FCS (FCS group).MCs and GEN proliferation was examined. Because the
In addition, both groups received different TSP peptideseffects of the type I peptides on MC proliferation could
be influenced by their adhesive properties, MC adhesion at concentrations of 0.1 to 100 mm. DNA synthesis was
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Table 1. Structures of TSP1 peptides
Abbreviation Peptide sequences Molecular wt Characterization
416 rv-amKRFKQDGGWSHWSPWSSC-ac 2176 Type I (antiangiogenic and TGFb-activating)
545 rv-amKRAKQAGGWSHWSPWSS-ac 1995 Antiangiogenic
475 rv-amKRFKQAGGASHASPASSC-ac 1873 TGFb-activating
513 rv-amKRAKQDGGASHASPASSC-ac 1797 Control
measured at 24 and 40 hours by a 12- or 28-hour pulse frequency of glomerular microaneurysms, the number of
proliferating MCs and GEN, the number of infiltrating(respectively) of [3H]thymidine incorporation into DNA
as described elsewhere [17]. To exclude effects on cell macrophages, the expression of the contractile protein
a-smooth muscle actin, and the expression of TGF-b1,toxicity, Trypan blue exclusion was performed at each
concentration of TSP peptides. as well as of extracellular matrix proteins such as collagen
IV and fibronectin were determined.The adhesion of rat MCs to a TSP-peptide matrix
was assayed using a hexosaminidase assay as described
Renal morphology and immunohistochemistrypreviously [18]. Microtiter plates (96 wells per plate)
were coated with 50 ml of the respective TSP peptide at Renal biopsies were fixed in methyl Carnoy’s solution,
concentrations of 50 to 400 mg/ml for one hour at 378C. embedded in paraffin, and cut into 5 mm sections for
Cells (50,000 or 25,000) were seeded per peptide-coated indirect immunoperoxidase staining as described else-
well. Cell-containing plates were incubated at 378C for where [21]. Sections were also stained with the periodic
one hour. A standard curve was prepared by plating acid Schiff reagent and were counterstained with hema-
1560 to 50,000 cells into noncoated wells. Optical density toxylin. For each biopsy, 40 to 70 cortical glomerular
was measured in the enzyme-linked immunosorbent cross-sections containing more than 20 discrete capillary
assay reader at 405 nm. segments each were evaluated in a blinded fashion in
regard to the following parameters: the total number
Animal model of nuclei (per glomerular cross section), the degree of
mesangiolysis, and the relative frequency of microaneu-Experimental mesangial proliferative glomerulone-
phritis (anti-Thy1 model) was induced in Wistar rats (180 rysms (percentage). Mesangiolysis was graded semi-
quantitatively using the following scale: 0 5 no mesangi-to 200 g; Simonson Laboratories, Gilroy, CA, USA) by
a single injection of goat antithymocyte antibody as de- olysis; I 5 segmental and focal mesangiolysis (less than
25% of the glomeruli show partial dissolution of thescribed elsewhere [19]. In this animal model, complete
anti-Thy1 antibody binding occurs within one hour [19]. mesangium); II 5 25 to 50% of the glomeruli are af-
fected; III 5 most (50 to 75%) glomeruli show severeTo avoid potential interference of the TSP peptides with
anti-Thy1 antibody binding and subsequent mesangio- mesangiolysis; and IV 5 global mesangiolysis, in which
virtually all glomeruli show a complete dissolution oflysis, the first TSP peptide injection was given three hours
after disease induction, when binding of the anti-Thy1 the mesangial areas. This score was assessed independent
of microaneurysm formation because in glomeruli withantibody to the mesangium had already occurred.
The experimental design of the in vivo study is shown microaneurysm, parts of the mesangial areas can still be
preserved or already be reconstituted.in Figure 1. In this experiment (injection of 0.5 ml anti-
Thy1 antibody per 100 g body wt), four to five rats per The following antibodies were used in this study: A
murine IgM monoclonal antibody (mAb) against thegroup were used. Group 1 received daily injections of
control peptide 513 (control), group 2 of type I peptide proliferating cell nuclear antigen (PCNA; 19A2; Coulter
Immunology, Hialeah, FL, USA); ED-1, a murine IgG1416 (anti-angiogenic and TGF-b activating), group 3 of
the anti-angiogenic peptide 545, and group 4 of the TGF- mAb to a cytoplasmic antigen present in monocytes,
macrophages, and dendritic cells (Serotec Ltd., Oxford,b–activating peptide 475. Renal biopsies, as described
previously, were performed on days 2 and 5, and the UK); OX-7, a murine IgG1 mAb specific for MCs (Sero-
tec); RECA-1, a murine IgG1 mAb specific for detectingexperiment was finished on day 8 [20, 21]. Renal biopsies
were fixed in methyl Carnoy’s, 10% formalin, and/or endothelial cells (Serotec) [22]; a-smooth muscle actin,
a murine IgG2 mAb specific for activated MC (SigmaOCT and were snap frozen. A 24-hour urine collection
for the measurement of protein and creatinine [21] was Chemical Co., St. Louis, MO, USA) [23]. Immunostain-
ing for matrix proteins was conducted with polyclonalstarted the day before the biopsy. Blood pressure mea-
surements were done twice before and twice after disease antibodies to collagen IV (goat antihuman/bovine colla-
gen IV; Southern Biotechnology Associates, Inc., Bir-induction. In renal biopsies, the total cell number per
glomerular cross section, the degree of mesangiolysis, the mingham, AL, USA), fibronectin (rabbit antirat fibro-
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nectin; Chemicon International, Inc., Temecula, CA, Dade Diagnostics, Aquado, Puerto Rico) [19]. Urinary
USA), TGF-b1 (rabbit antihuman TGF-b1; Santa Cruz creatinine was measured using an autoanalyzer (Beck-
Biotechnology Inc., Santa Cruz, CA, USA) and a murine man Instruments, Brea, CA, USA). Systolic blood pres-
IgG1 mAb against TSP1 (Dunn, Labortechnik GmbH, sure was measured by tail plethysmography in condi-
Asbach, Germany). Negative controls for immunostain- tioned, conscious rats [27].
ing included either deleting the primary antibody or sub-
Statistical analysisstitution of the primary antibody with equivalent concen-
trations of an irrelevant murine mAb or preimmune All values are expressed as mean sd. Statistical signifi-
rabbit IgG. For each biopsy, 40 to 70 glomerular cross- cance (defined as a P of less than 0.05) was evaluated
sections were evaluated in a blinded fashion. Glomerular using the Student’s t-test or one-way analysis of variance
expression of collagen IV, fibronectin, and a-smooth with modified t-test using the Bonferroni method.
muscle actin was graded semiquantitatively [24] and re-
flected changes in the area and intensity of mesangial
RESULTSstaining: 0 5 very weak or absent staining; 11 5 weak
staining with less than 25% of the glomerular tuft show- In vitro studies
ing focally increased staining; 21 5 25 to 49% of the
Anti-angiogenic thrombospondin peptides inhibit mes-glomerular tuft with focally increased staining; 31 5 50
angial cell proliferation in response to cytokines. Cellto 75% of the glomerular tuft demonstrating increased
proliferation was measured by a 12- and 28-hour pulse ofstaining; 41 5 more than 75% of the glomerular tuft
[3H]thymidine incorporation into DNA with equivalentstained strongly. We and others have previously shown
results. Representative results of the 28-hour pulse label-that this scoring system is reproducible between different
ing are shown in Figure 2 A, B, and C and were equiva-observers and that the data obtained are highly corre-
lent for the 12-hour labeling group. Stimulation of MClated with those obtained by computerized morphometry
growth with 10 ng/ml FGF-2 or 10 ng/ml PDGF-BB[25, 26].
increased [3H]thymidine incorporation into DNA two-
Immunohistochemical double staining fold to threefold compared with growth-arrested MCs
(0.5% FCS). Concentrations of 0.1 or 1 mm of TSP pep-To determine the number of proliferating MCs or
tides did not influence proliferative activity of unstimu-GEN, double immunostaining for PCNA, a marker of
lated or stimulated MC. Concentrations of 10 to 100 mmcell proliferation, and OX-7, a MC-specific marker or
RECA-1, an endothelial cell-specific marker was per- of the type I domain peptide (416) caused a significant,
formed as described previously [4]. Briefly, the first pri- concentration-dependent decrease in DNA synthesis in
mary antibody (OX-7 or RECA-1) was incubated over- growth arrested, FGF-2, or PDGF-BB–stimulated MCs
night at 48C, followed sequentially by biotinylated rabbit (Fig. 2 A, B). To define further whether the anti-angio-
antimouse IgG1 serum (Zymed, San Francisco, CA, genic action or activation of latent TGF-b by the type I
USA), peroxidase conjugated Avidin D (Vector, Bur- peptide is required for this marked antiproliferative ef-
lingame, CA, USA), and color development with diami- fect, additional peptides with either the anti-angiogenic
nobenzidine without nickel chloride. Incubation in 3% (545) or TGF-b–activating (475) sequence were tested.
H2O2/methanol for 20 minutes prevented any remaining These experiments demonstrated that the anti-angio-
peroxidase activity. Subsequently, the second primary genic (545) sequence alone mimicked the effects of the
antibody (PCNA) was applied overnight at 48C, followed type I peptide on MC proliferation (but was a little less
by peroxidase-conjugated rat antimouse IgM antibody effective). In contrast, the TGF-b–activating (475) se-
(Zymed) and diaminobenzidine with nickel chloride as quence did not reduce MC proliferation at any tested
the second color reagent. The controls for all double concentration. In addition, a panspecific TGF-b–blocking
staining procedures consisted of either omitting one of
antibody (R&D Systems, Minneapolis, MN, USA) at con-
the secondary antibodies and of omitting or replacing
centrations of 0.01, 0.1, or 1.0 mg/ml did not influenceeither one of the primary antibodies with an irrelevant
the antiproliferative effect of the type I peptide.mouse mAb. The number of proliferating MCs or GEN
Stimulation of MCs with 10% FCS increased DNAwas evaluated by counting the number of cells that
synthesis 4- to 12-fold depending on the [3H]thymidinestained for both PCNA (black) and OX-7 (brown) or
pulse period. Despite the marked decrease in prolifera-RECA-1 (brown) as PCNA1/OX-71 or PCNA1/RECA-
tive activity of serum-starved, FGF-2, or PDGF-BB–11 cells, respectively, and was expressed as a mean 6
stimulated MC by the type I domain peptide, TSP pep-sd per glomerular cross-section.
tides did not inhibit [3H]thymidine uptake into DNA of
Miscellaneous measurements 10% FCS-stimulated MCs (Fig. 2C). Peptide-treated
cells excluded trypan blue, demonstrating that TSP pep-Urinary protein was measured by the sulfosalicyclic
acid method with whole serum standards (Lab Trol; tides did not affect MC viability.
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Fig. 2. Type I (416) and the anti-angiogenic (545) peptides inhibit mesangial cell (MC) and glomerular endothelial cell (GEN) proliferation in
vitro. Representative results of the [3H]thymidine incorporation into DNA after pulse labeling are shown. The concentration-dependent inhibition
of cell proliferation by TSP-peptides (h) 416 and (e) 545 (but not by the TGF-b–activating peptide 475, n) versus the control peptide 513 (s)
in serum-starved (0.5% FCS, A) and in FGF-2 or PDGF-BB–stimulated (B) cultured MCs is demonstrated (h, 513 control; 475 TGF-b; ,
anti-angiogenic; , 416 type I), whereas these peptides did not inhibit cell proliferation in 10% FCS-stimulated MCs (C). Symbols in C, D and
F are: (s) 513 control; (n) 475 TGF-b; (e) 545 anti-angiogenic; (h) 416 type I. GEN proliferation was dose dependently inhibited by peptides
416 and 545 (but not 475) versus the control peptide 513, as demonstrated in serum-starved (0.5% FCS; D), FGF-2–stimulated (E), and 10% FCS-
stimulated (F) cultured cells. Symbols in E are: (h) 513 control; ( ) 475 TGF-b; ( ) anti-angiogenic; ( ) 416 type I. Abbreviations are in the
Appendix.
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Anti-angiogenic thrombospondin peptides have marked
suppressive effects on glomerular endothelial cell prolifer-
ation to cytokines. Figure 2 D, E, and F show representa-
tive results of the effect of the type I domain peptide on
[3H]thymidine incorporation for 28 hours in GEN, and
equivalent results were obtained after a 12-hour labeling
period. Stimulation of serum-starved GEN (0.5% FCS)
with 10 ng/ml FGF-2 or 10% FCS increased DNA syn-
thesis twofold to sixfold depending on the [3H]thymidine
pulse period (Fig. 2 D–F). Similar to the effects on cul-
tured MCs, concentrations of 0.1 or 1 mm of TSP peptides
did not influence proliferative activity of GEN grown in
0.5% FCS (serum starved). Concentrations of greater
than 10 mm of the type I domain peptide (416) caused
a significant, concentration-dependent decrease in DNA
synthesis in serum-starved or FGF-2–stimulated GEN Fig. 3. Mesangial cells (MCs) and glomerular endothelial cells (GEN)
(Fig. 2 D, E). In contrast to the effects on cultured MCs, adhere to a matrix of thrombospondin (TSP)-peptides 416 (type I; h)
or 545 (anti-angiogenic; e), but not to 475 (TGF-b–activating; n) orthe type I peptide (416) also dose dependently decreased
513 (control; s). Using an attachment assay, only peptides 416 and 545proliferation of cultured GEN stimulated with 10% FCS
were adhesive components for cultured MCs, whereas MCs did not
(Fig. 2F). Again, the anti-angiogenic sequence (545) attach to a matrix of peptide 475 or 513.
alone was comparable in reducing GEN proliferative
activity compared with the type I peptide, whereas the
TGF-b–activating peptide (475) did not significantly
wt and was maximal at concentrations higher than 3change DNA synthesis (Fig. 2 D–F). GEN viability, as
mg/kg body wt. Continuous intravenous infusion of typetested by trypan blue exclusion, was not affected by TSP
I peptide via jugular vein catheter [28] and osmotic mini-peptides at the concentrations used in this study.
pumps (Alzet Corp., Palo Alto, CA, USA) in a subsetCultured mesangial cells adhere to a matrix of the anti-
of animals did not seem to enhance the effectiveness ofangiogenic thrombospondin peptides. To test if the anti-
the peptide markedly.proliferative effects of the type I (416) or anti-angiogenic
In a second anti-Thy1 (0.3 ml/100 g body wt) pilotpeptide (545) on cultured MCs are associated by/with
study, four rats per group were used: Group 1 receivedits adhesive action, we investigated the ability of cultured
daily injections of the control peptide 513. Group 2 ofMCs to attach to peptides 416, 545, or 475 compared
the type I peptide 416, and group 3 of the anti-angiogenicwith a control peptide (513) matrix. More than 70% of
peptide 545. Survival biopsies were done on days 2 andtrypsinized MCs adhered within one hour to a type I
5, and sacrificial biopsies were done on day 9. The resultspeptide matrix, as shown in Figure 3. Less than 2% of
of this pilot study demonstrated marked protective ef-the MC attached to a control peptide matrix. Again, the
fects of the type I (416) and also of the anti-angiogenicanti-angiogenic peptide alone (545) mimicked the effect
(545) peptide with regards to the MC and GEN responseof the type I peptide, whereas the TGF-b–activating
to injury as well as to renal function as shown in Tablepeptide (475) was uneffective (Fig. 3).
2 on the left.
In vivo studies Based on these findings in the pilot experiments, the
study design was adapted the following way: (a) ThePilot studies. In a first pilot study, 0.3 ml/100 g body
type I peptide was given as daily injections at a concen-wt of the anti-Thy1 antibody were injected, followed by
tration of 3 mg/kg body wt, and all other peptides weredaily injections of different amounts (0.1 mg, 0.5 mg, 1
applied at equal molarities (1.6 mm/day). (b) To investi-mg, 3 mg, or 10 mg per kg body weight, N 5 2 to 4
gate whether activation of TGF-b is also involved ineach) of the d-reverse type I peptide (416) or the control
some of the effects of the type I peptide, an additionalpeptide (513). No side effects were observed in compari-
group of rats was treated with peptide 475 that specifi-son to an anti-Thy1/PBS group. All rats looked healthy,
cally activates TGF-b in in vitro assays, but does notwere active, gained weight, and did not have signs of
inhibit angiogenesis. (c) To investigate whether TSP pep-infection or diarrhea. No histological or immunohisto-
tides can also suppress microaneurysm formation as achemical changes were seen comparing the control pep-
presumed consequence of severe GEN injury, the anti-tide 513 to PBS-treated anti-Thy1 animals. In contrast,
Thy1 dose was increased to 0.5 ml/100 g body wt [21],a dose-dependent decrease of MC proliferation by the
leading to enhanced and prolonged mesangiolysis, in-type I peptide started at a concentration of 0.5 mg/kg
body wt was already quite pronounced at 1 mg/kg body creased GEN injury, GEN proliferative response and
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the frequent development of microaneurysm (5 to 8% nificant values anymore (Table 2). TGF-b peptides
of glomeruli on day 5 in control animals). A dose of 0.3 tended to increase fibronectin or collagen IV accumula-
ml anti-Thy1 antibody per 100 g body wt in the pilot tion compared with the other groups, but did not reach
studies induced a shorter phase of mesangiolysis, with a significance. In addition, immunostaining for TGF-b1
short, but prominent, mesangial proliferative phase from protein did not show significant differences in the differ-
days 2 through 6, but with a less pronounced GEN prolif- ent peptide groups in this experiment.
erative response and a lack of microaneurysm formation.
Thrombospondin peptides inhibit glomerular
Effect of the thrombospondin peptides on the endothelial cell proliferation and microaneurysm
mesangial cell response to injury in experimental formation in experimental mesangial
mesangial proliferative glomerulonephritis proliferative glomerulonephritis
Mesangial cell proliferation. Glomerular MC prolifer- Glomerular endothelial cell proliferation was exam-
ation was determined by double immunostaining using ined by double immunostaining using an antibody to
an antibody to PCNA, a marker of DNA synthesis, and PCNA, a marker of DNA synthesis, and an antibody
an antibody to OX-7, a marker specific for MCs. Figure to RECA-1 that is specific for endothelial cells [22].
4 and Table 2 show the effects of TSP peptides on MC Mesangiolysis was accompanied by GEN injury and a
proliferation (OX71/PCNA1 cells) during the time 17-fold increase in GEN proliferation on day 2 of disease.
course of experimental glomerulonephritis. In rats that Figure 5A shows the effects of TSP peptides on GEN
received daily injections of the control peptide 513, there proliferation (identified as RECA11/PCNA1 cells) on
was a fourfold increase in the number of proliferating day 2 in the anti-Thy1 model. The type I domain (416) or
MC (OX-71/PCNA1) at day 2, a 20-fold increase at the anti-angiogenic peptide (545) significantly decreased
day 5, and an 8-fold increase at day 8 compared with GEN proliferation on day 2 of the disease compared
normal rats. Injections of the type I domain peptide with control peptide 513 (Table 2 and Fig. 5A), whereas
reduced the number of PCNA1/OX71 cells by 40% on the TGF-b–activating peptide was without any effect.
days 5 and 8 (Table 2 and Fig. 4A). Figure 4 D and E Figure 5C (control peptide) and 5D (type I peptide) show
show representative pictures of MC proliferation representative double stains for PCNA and RECA-1 on
(PCNA/OX-7 double staining) in the control (Fig. 4D) day 2 in the anti-Thy1 model.
and the type I peptide group (Fig. 4E). The reduction Because mesangiolysis is thought to affect GEN injury
in MC proliferation by type I peptide (416) was associ- and function indirectly, mesangiolysis was assessed by a
ated with a significant decrease in glomerular cellularity.
semiquantitative scoring system. A very severe but equalGlomerular cell number (by periodic acid-Schiff stain)
mesangiolysis (score about 3.8) in all groups was seenon day 5 of anti-Thy1 disease was 76.1 6 5.2 cells per
on day 2 of disease. Because microaneurysms are thoughtglomerular cross section in the type I peptide group
to develop as a consequence of GEN stretching andversus 94.6 6 8.4 cells in the control group. A significant
denudation [3], we also investigated whether microane-but less pronounced reduction of MC proliferation was
urysm formation was affected by TSP peptides. The anti-also found in the group of animals treated with the anti-
angiogenic and less prominent type I domain peptideangiogenic peptide (545), whereas the TGF-b–activating
decreased microaneurysm formation at day 5 (Fig. 5B).sequence (475) did not reach significant values.
Mesangial cell activation. De novo expression of a- Anti-angiogenic peptides reduce proteinuria
smooth muscle actin during the time course of mesangial and improve renal function in
proliferative glomerulonephritis is considered to be a experimental glomerulonephritis
specific marker of MC activation. a-smooth muscle actin
During the time course of the anti-Thy1 model, 24-immunostaining on day 8 was markedly decreased in the
hour proteinuria in rats was maximally increased at thetype I or the anti-angiogenic peptide group compared
mesangiolytic phase (up to 30 times vs. controls) andwith control animals (Table 2 and Fig. 4B), whereas
declined during the proliferative phase (days 3 to 7)no significant effect was seen in the TGF-b–activating
to reach normal values after 10 to 14 days. The anti-peptide group. Representative examples of a-smooth
angiogenic and less pronounced the type I peptide dra-muscle actin immunostaining in the control animals (Fig.
matically reduced proteinuria (almost down to normal4F) and in the type I peptide-treated animals (Fig. 4G)
values; Table 2 and Fig. 6). The urine protein/creatinineon day 8 are shown.
ratio was markedly improved by the antiangiogenicExtracellular matrix accumulation. Although extra-
(0.3 6 0.06) or type I (0.64 6 0.15) peptide comparedcellular matrix accumulation was significantly decreased
with control (2.0 6 0.4) peptide treatment. In contrast,by the type I or the anti-angiogenic peptide in the pilot
TGF-b–activating peptide treatment resulted in a urinestudy, the inhibition of fibronectin or collagen IV accu-
protein/creatinine ratio (3.5 6 1.0) that was worse versusmulation in this experiment using the higher anti-Thy1
antibody dose (0.5 ml/100 g body wt) did not reach sig- controls (P , 0.05).
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Table 2. Quantitation of proliferating MC (OX-71/PCNA1 cells), MC-activation (a-smooth muscle actin; a-sm actin1), matrix expansion
(fibronectin, collagen IV staining), proliferating GEN (RECA-11/PCNA1 cells), glomerular
microaneurysm formation, macrophage influx (ED-1), proteinuria, and systolic blood pressure
Anti-Thy 1 model Body wt 0.3 ml/100 g Body wt 0.5 ml/100 g
Effects on Peptide day 2 day 5 day 9 day 2 day 5 day 8
Proliferating MC control/513 3.861.2 12.063.4 1.160.4 1.860.7 7.661.5 3.260.6
(OX-71/PCNA1 TGF-b/475 ND ND ND 1.060.3 6.561.6 3.460.4
cells/glomerulus) anti-ang./545 2.560.3a 8.060.7a 1.260.4 1.560.7 5.361.2a 2.260.5
type 1/416 2.0 60.3a 6.361.9a 1.260.6 1.360.8 4.761.4a 1.860.3a
MC activation control/513 0.760.2 3.160.3 1.660.3 0.360.1 2.160.5 1.860.1
a-sm actin, TGF-b/475 ND ND ND 0.360.1 2.460.5 2.160.2
score 0–4) anti-ang./545 0.560.2 2.460.2a 1.260.2 0.460.3 1.960.2 1.260.3a
type 1/416 0.3 60.1a 1.960.3a 0.760.3a 0.560.3 1.860.1 1.260.3a
MC matrix expansion control/513 0.560.1 2.860.2 1.560.1 0.460.1 1.160.2 2.060.2
(fibronectin, TGF-b/475 ND ND ND 0.760.2 1.360.2 2.360.2
score 0–4) anti-ang./545 0.460.2 2.260.2a 1.260.2 0.360.1 1.060.3 1.860.1
type 1/416 0.4 60.2 1.860.2a 0.860.2a 0.360.1 1.060.2 1.860.1
MC matrix expansion control/513 0.660.2 2.460.3 0.960.1 0.460.2 1.360.3 1.960.3
(collagen IV, TGF-b/475 ND ND ND 0.660.1 1.560.2 2.360.3
score 0–4) anti-ang./545 0.460.2 1.860.2a 0.760.1 0.460.1 1.060.3 1.760.2
type 1/416 0.4 60.2 1.360.1a 0.360.2a 0.560.1 0.960.2 1.560.2
Proliferating GEN control/513 0.760.3 ND ND 2.060.4 ND ND
(RECA-1/PCNA TGF-b/475 ND ND ND 2.160.6 ND ND
cells/glomerulus) anti-ang./545 0.260.1a ND ND 0.560.2a ND ND
type 1/416 0.1 60.1a ND ND 0.260.2a ND ND
Glomerular micro- control/513 ,1% ,1% ,1% ,1% 6.663.0 ND
aneurysm % TGF-b/475 ND ND ND ,1% 4.264.2 ND
anti-ang./545 ,1% ,1% ,1% ,1% 0.560.6a ND
type 1/416 ,1% ,1% ,1% ,1% 2.362.0 ND
Macrophage influx control/513 12.262.3 ND ND 12.061.5 10.661.6 5.861.8
ED-11 cells/ TGF-b/475 ND ND ND 11.160.6 9.360.8 5.260.9
glomerulus anti-ang./545 10.862.4 ND ND 10.161.0 8.361.2 4.861.0
type 1/416 11.3 62.0 ND ND 10.060.8 9.661.3 5.061.3
Proteinuria control/513 199656 42624 1165 100638 49610 1366
mg/24 hr TGF-b/475 ND ND ND 99673 42615 1367
anti-ang./545 3066a 1662a 1363 863a 18610a 561a
type 1/416 21 610a 1164a 1163 31618a 41615 1466
Systolic blood control/513 ND ND ND 12165 11365 11765
pressure mm Hg TGF-b/475 ND ND ND 12067 118614 11567
anti-ang./545 ND ND ND 127615 129612 126613
type 1/416 ND ND ND 127614 122610 11565
ND means not done. Values are mean 6 sd. Abbreviations are in the Appendix.
a P , 0.05
Thrombospondin peptides did not alter macrophage mans) [1]. The administration of the type I peptide to
diseased animals provided remarkable protection: al-influx or blood pressure
most complete suppression of proteinuria, decreased MCThe number of infiltrating macrophages/monocytes
proliferation, and activation, as well as a decrease inwas examined by immunostaining for ED-1, and no
GEN proliferation and microaneurysm formation. Mostchanges in the different groups were seen at any time
of this protection appeared to be related to the anti-point studied (Table 2). Because a decrease in systemic
angiogenic sequence in the type I domain.blood pressure might affect renal function, systolic blood
pressure was measured twice before and twice after dis-
In vitro studies undertaken to determine the effect of
ease induction in all animals of this experiment (Table
the type I domain peptides
2). None of the TSP peptides affected systolic blood
The type I peptide mainly consists of a basic aminopressure levels in diseased rats (Table 2).
acid motif adjacent to a WSXW motif that has been shown
to inhibit angiogenesis [7] and a second sequence that can
DISCUSSION activate latent TGF-b in vitro [10]. Consistent with the in
vitro effect of the mature TSP1 protein [5, 29], the typeWe examined the effect of synthetic peptides to the
type I domain of the TSP1 molecule in an inflammatory I peptide markedly reduced proliferation of unstimulated,
FGF-2, or 10% FCS-stimulated cultured GEN. In contrastrat model of mesangial proliferative glomerulonephritis
(the most common type of glomerulonephritis in hu- to the whole TSP1 molecule that mildly stimulates prolif-
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Fig. 4. Type I (416) and anti-angiogenic (545) peptides inhibit mesan-
gial cell (MC) proliferation (OX-7/PCNA immunostaining) and activa-
tion (a-smooth muscle actin immunostaining) in vivo in mesangial
proliferative glomerulonephritis. ATS is anti-thymocyte serum. Glo-
merular MC proliferation was determined by double immunostaining
using an antibody to PCNA, a marker of cell proliferation, and an
antibody to OX-7, a marker specific for MC. (A) The quantitation of
MC proliferation (identified as OX71/PCNA1 cells) during the time
course of experimental glomerulonephritis. Symbols are: (s) 513 con-
trol; (n) 475 TGF-b activation; (e) 545 anti-angiogenic; (h) 416 type
I. (B) Quantitation of the glomerular de novo expression of a smooth
muscle actin, a specific marker of MC activation, during the time course
of the anti-Thy1 model. (C) The data obtained for glomerular collagen
IV staining during disease. The star marks significant differences (P ,
0.05) versus the control group (513). (D and E) Representative double
stains for PCNA and OX-7 at day 5 of disease. Proliferating cells were
identified by nuclear staining for PCNA in black, and MC were identified
by the cytoplasmic stain of the OX-7 antigen in brown. The type I
peptide treated rats (E) had a marked decrease in the number of
proliferating MC (PCNA1/OX-71) compared with rats treated with
the control peptide (D). (F and G) These demonstrate the decreased
de novo expression of a-smooth muscle actin (black color) in the type
I peptide groups (G) versus the control group (F) on day 8 of disease.
eration of cultured MCs [30] and other mesenchymal cells, observation that these peptides inhibited both FGF-2
and PDGF-BB–mediated MC proliferation, but notthe type I peptide also inhibited proliferation of unstimu-
lated, FGF-2, or PDGF-BB–stimulated cultured MCs. In- FCS-stimulated MC proliferation, suggested the pres-
ence of other growth factors in FCS that are not suppress-terestingly, in MCs that were stimulated with 10% FCS,
the antiproliferative activity of the type I peptide was ible by the anti-angiogenic peptides. Another explana-
tion is that the antiproliferative effects of the peptidesabolished. Although the proliferative activity of the TSP1
molecule is thought to be related to the aminoterminal, are linked to adhesion, as only those peptides that medi-
ated MC adhesion (the type I domain and anti-angio-heparin-binding domain [30], the antiproliferative activity
of the type I peptide in both GEN and MC was related genic peptides) were also antiproliferative [31].
to the anti-angiogenic sequence, as peptides with this
Effects of thrombospondin-1 peptides in a model ofsequence alone had similar effects. In addition, the anti-
mesangial proliferative glomerulonephritis in the ratproliferative effect of the type I peptide was independent
of its potential effect on TGF-b, because the TGF-b– The first major in vivo finding was that the type I
peptide markedly reduced MC proliferation (up to 40%)activating sequence alone (peptide 475) was ineffective
and the TGF-b–blocking antibody failed to significantly and MC activation [20] in the anti-Thy1 model. The
better effectiveness in regard to matrix reduction by thereverse the effect of the type I peptide. This result was
unexpected because TGF-b is known to inhibit MC pro- type I peptide in the pilot study compared with the final
experiment may relate to its greater reduction of theliferation, but may possibly be due to competition with
endogenously produced TSP1 by the cultured MCs. The more prominent MC proliferative response in the pilot
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Fig. 5. Type I (416) and anti-angiogenic peptide (545) inhibit GEN proliferation and microaneurysm formation in experimental glomerulonephritis.
ATS is anti-thymocyte serum. GEN proliferation was determined by double immunostaining using an antibody to PCNA, a marker of DNA
synthesis, and an antibody to RECA-1 that is specific for endothelial cells. On day 2, GEN proliferation was increased approximately 17-fold in
the anti-Thy1 model versus healthy control rats. (A) The effects of TSP-peptides on GEN proliferation (identified as RECA11/PCNA1 cells)
on day 2 in the anti-Thy1 model where the type I (416; ), and the anti-angiogenic peptide (545; ) significantly decreased GEN proliferation
compared with the control peptide (513; h), whereas the TGF-b–activating peptide (475; ) did not. (B) This demonstrates the quantitation of
the percentage of glomerular microaneurysm formation at the peak on day 5 of disease, where in particular, the antiangiogenic peptide alone
(545; ) almost completely prevented microaneurysm formation, whereas the type I peptide (416; ) was not equally effective. The star marks
significant differences (P , 0.05) versus the control group (513; h). (C and D) Representative double stains for PCNA (nuclear black stain) and
RECA-1 (brown) at day 2 of disease. Administration of the type I (416) peptide (D) resulted in a marked decrease in the number of proliferating
GEN (PCNA1/RECA-11 , arrows) compared with rats treated with the control peptide (C). PCNA-/RECA-11 nonproliferating GEN are marked
with long arrowheads, and PCNA1/RECA-1- cells (probably proliferating MC) are marked by a short arrowhead. (E, peptide 513 control group,
and F, antiangiogenic peptide 545) The prevention of microaneurysm formation (by periodic acid-Schiff stain) by the antiangiogenic peptide (545)
at the peak on day 5 of disease.
study because MC proliferation and matrix expansion in vivo but was less effective in inhibiting MC-specific
are frequently linked [2]. The second major in vivo find- responses compared with the type I peptide. In contrast,
ing was that treatment with the type I peptide dramati- the anti-angiogenic peptide 545 was equivalent (GEN
cally decreased GEN proliferation in vivo and reduced proliferation) or even more (prevention of microaneur-
development of glomerular microaneurysms. Assuming ysm formation) effective in the protection of GEN injury
that microaneurysm formation (peaking on day 5) results compared with the type I peptide, which is again in
from rupture of the injured glomerular endothelium [3], agreement with the in vitro studies. In addition, the anti-
the reduction of microaneurysm formation in the type I angiogenic peptide suppressed proteinuria and improved
peptide group suggests a protective effect on the glomer- renal function in diseased rats better than the type I
ular endothelium. The third major finding of this study peptide. The mechanisms for the protective effects of
was that the type I peptide dramatically reduced protein- the anti-angiogenic TSP peptides may well include antag-
uria in both anti-Thy1 models. In this glomerulonephritis onism of FGF-2, as a recent study of our group with
model, proteinuria is maximal during the mesangiolytic blocking FGF-2 antibodies showed similar results [32].
phase (days 1 to 3), declines during the proliferative Nevertheless, the in vitro studies also demonstrate effects
phase (days 4 to 7), and is almost normal after day 8 on PDGF-BB–mediated MC proliferation and suggest
(Table 2). The inhibition of GEN proliferation and mi- independent adhesive mechanisms of the anti-angiogenic
croaneurysm formation by TSP peptides correlates well
peptides.with the decrease in proteinuria in this model. Therefore,
it is tempting to speculate that GEN injury can be a Transforming growth factor-b–activating peptide (475)
critical determinant of proteinuria, although the mecha- is not effective in experimental kidney disease
nism of proteinuria in this model is not yet established.
Because TGF-b is known to inhibit proliferation of
Effects on mesangial and glomerular endothelial cell mesenchymal cell types including the MCs [33], the anti-
injury in experimental glomerulonephritis are proliferative effects of the type I peptide could also be
largely due to the anti-angiogenic sequence mediated through activation of TGF-b. Consistent with
of the type I peptide the in vitro results, the TGF-b–activating sequence alone
was not able to cause significant effects in regard toConsistent with the in vitro studies, the anti-angiogenic
peptide (545) alone had similar effects on MC injury proteinuria, as well as the MC or GEN response to injury
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blood pressure in rats, both of which were unchanged
in all groups.
In summary, we report that peptides from the proper-
din-like type I repeats of the TSP molecule effectively
inhibit MC and GEN proliferation in vitro and in vivo
in experimental mesangial proliferative glomerulone-
phritis. Moreover, the inhibition of glomerular cell prolif-
eration was associated with decreased MC activation,
prevention of microaneurysm formation, and an almost
complete suppression of proteinuria during the disease
process. These effects are mainly due to the anti-angio-
genic sequence, and mechanisms of these actions may
include antagonism of FGF-2, but also adhesive proper-
ties of this peptide. Our study suggests that the type I
and anti-angiogenic TSP1 peptides should be consideredFig. 6. Type I (416; h), and in particular the anti-angiogenic peptide
(545; e) suppress proteinuria in experimental glomerulonephritis. as a potential future treatment for many glomerular dis-
Other symbols are: (n) 475, TGF-b activating peptide; (s) 513 control. ease processes, where hypercellularity and severe pro-ATS is anti-thymocyte serum.
teinuria may frequently lead to chronic progressive kid-
ney disease usually to the date ending in dialysis [35].
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